Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(reslizumab)
202 results
  • A drug safety review of treating eosinophilic asthma with monoclonal antibodies. [Journal Article]
    Expert Opin Drug Saf 2019; :1-10Mitchell P, Leigh R
  • Introduction: The last two decades have seen significant progress in the treatment of severe asthma especially the severe eosinophilic phenotype. This review article serves to update the reader on the known safety profiles of these medications. It does not serve as a review of their clinical efficacies. Areas covered: All four of the currently approved monoclonal antibodies (biologics) used in th…
  • What have recent advances in therapy taught us about severe asthma disease mechanisms? [Journal Article]
    Expert Rev Clin Immunol 2019; :1-9Caminati M, Polk B, Rosenwasser LJ
  • Introduction: Severe asthma still represents a worldwide challenge. The need for further treatment options has stimulated basic and pharmacological research to focus on the immune and inflammatory background of asthma. The new biologic drugs express the considerable advances in the field and besides providing a revolutionary treatment option for severe asthma, contribute themselves to better unde…
  • New treatments for chronic urticaria. [Review]
    Ann Allergy Asthma Immunol 2019Kolkhir P, Altrichter S, … Maurer M
  • CONCLUSIONS: Novel and better treatments for CU are very much needed. Some agents are in clinical trials already (eg, ligelizumab), and additional ones should be developed, making use of the many promising targets recently identified and characterized.
  • Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. [Review]
    Respir Res 2019; 20(1):179Edris A, De Feyter S, … Lahousse L
  • Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate. PubMed and Web of Science were searched for phase II and phase III randomized clinical trials with monoclonal antibodies targeting key mediators of type 2-associated asthma. Thirty trials were selected in…
  • Targeting eosinophils: severe asthma and beyond. [Review]
    Drugs Context 2019; 8:212587Caminati M, Menzella F, … Senna G
  • Recent research in the field of bronchial asthma has mainly focused on eosinophilic disease phenotype. Several trials proved the efficacy and safety profile of eosinophils and interleukin (IL)-5 targeting molecules, currently approved for severe asthma and available on the market. They include mepolizumab and reslizumab, IL-5 blocking molecules, and benralizumab, targeting the IL-5 receptor and e…
New Search Next